Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Luis Labeaga"'
Publikováno v:
Drugs in Context, Pp 1-13 (2017)
Background: Bilastine is a safe and effective commonly prescribed non-sedating H1-antihistamine approved for symptomatic treatment in patients with allergic disorders such as rhinoconjunctivitis and urticaria. It was evaluated in many patients throug
Externí odkaz:
https://doaj.org/article/98a9e40b4fb440618638149fe1c53e40
Autor:
Jimena Coimbra, Montserrat Puntes, Ignasi Gich, Joan Martínez, Pol Molina, Rosa Antonijoan, Cristina Campo, Luis Labeaga
Publikováno v:
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction: The aim of this study was to compare the pharmacodynamic activity of bilastine administered under fasting and fed conditions in healthy volunteers. Methods: In this randomized, open-label, two-period, crossover study involving 24 health
Autor:
Anahí Yáñez, Aintzane García-Bea, Luis Labeaga, Monica Rodriguez, Valvanera Vozmediano, Cristina Campo, Zoltán Novák
Publikováno v:
European Journal of Pediatrics
Bilastine, a second-generation antihistamine, is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children aged ≥ 6 years. Pharmacokinetic data for children aged 6–11 years were extracted post hoc f
Autor:
Aintzane García-Bea, José Ramón Azanza, Cristina Campo, Luis Labeaga, Belén Sádaba, Román Valiente
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 45:265-272
Bilastine is a non-sedating H1 antihistamine indicated for the treatment of allergic rhinoconjunctivitis and urticaria. The aim of this trial was to assess the bioequivalence of three novel pediatric oral formulations of bilastine. An open label, ran
Autor:
John C. Lukas, Luis Labeaga, Ander Sologuren, Román Valiente, Cristina Campo, Monica Rodriguez, Stephan Schmidt, Valvanera Vozmediano, Esther Encinas
Publikováno v:
European Journal of Pharmaceutical Sciences. 128:180-192
Bilastine is a non-sedating second-generation H1 antihistamine approved for treatment of allergic rhinoconjunctivitis (AR) and urticaria (U) in adults at the oral (p.o.) dose of 20 mg once daily (OD). Optimal attributes can be anticipated for its cli
Publikováno v:
Bosma, R, van den Bor, J, Vischer, H F, Labeaga, L & Leurs, R 2018, ' The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H 1 receptor ', European Journal of Pharmacology, vol. 838, pp. 107-111 . https://doi.org/10.1016/j.ejphar.2018.09.011
European Journal of Pharmacology, 838, 107-111. Elsevier
European Journal of Pharmacology, 838, 107-111. Elsevier
Drug-target binding kinetics has recently attracted considerable interest in view of the potential predictive power for in vivo drug efficacy. The recently introduced antihistamine bilastine has a long duration of in vivo drug action, which outlasts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47b2804d5f41b263a38e2b63d835479d
https://hdl.handle.net/1871.1/f4ba4659-e14c-4643-a1ec-7a353a0ecafd
https://hdl.handle.net/1871.1/f4ba4659-e14c-4643-a1ec-7a353a0ecafd
Publikováno v:
European journal of pharmacology. 838
Drug-target binding kinetics has recently attracted considerable interest in view of the potential predictive power for in vivo drug efficacy. The recently introduced antihistamine bilastine has a long duration of in vivo drug action, which outlasts
Autor:
Ander Sologuren, Manuel Ruiz-Miján, Sonia Fernández, Luis Labeaga, Rosa Viñas, María Del Mar Forés, Susana E Riesgo, María Rosa Senán, Esther Cordón
Publikováno v:
Allergy and asthma proceedings. 39(4)
Background Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by ty
Autor:
Kazuhiko Yanai, Luis Labeaga, Johannes G. Ramaekers, Román Valiente, Esther Redondo, Magí Farré, Ignacio Jáuregui
Publikováno v:
Expert Opinion on Drug Safety. 15:89-98
Introduction: Rational selection of a second-generation H-1-antihistamine requires efficacy and safety considerations, particularly regarding central nervous system (CNS) effects (cognitive and psychomotor function), potential for driving impairment,
Autor:
Román Valiente, Jimena Coimbra, Consuelo García-Gea, Cristina Campo, Luis Labeaga, Ignasi Gich, Montserrat Puntes, Rosa M. Antonijoan
Publikováno v:
CURRENT MEDICAL RESEARCH AND OPINION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Objective: To compare the peripheral antihistaminic activity of bilastine, rupatadine and desloratadine in inhibiting the histamine-induced wheal and flare (W&F) response. Research design and methods: Twenty-four healthy volunteers aged 18-40 years p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5fd138b910fc2400a2d1bb1203e5653
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6771
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6771